J&J los­es at­tempt to ex­tend patent in In­dia for tu­ber­cu­lo­sis drug

In­dia’s patent of­fice de­nied John­son & John­son’s at­tempt to ex­tend the com­pa­ny’s patent on a for­mu­la­tion of be­daquiline, which is used to treat drug-re­sis­tant tu­ber­cu­lo­sis, un­til 2027.

Crit­ics of the com­pa­ny’s move to file a sec­ondary patent say the of­fice’s de­ci­sion means a mo­nop­oly on the drug is over, at least in In­dia, in part thanks to a 2019 chal­lenge filed by two TB sur­vivors, Nan­di­ta Venkate­san and Phumeza Tisile. They ar­gued that ap­prov­ing the patent would block man­u­fac­tur­ers’ abil­i­ty to make gener­ics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.